Multi Arm Optimization News Today

Recent research suggests that adding blood thinners to clot-busting medication after an ischemic stroke may not be necessary, as it does not improve the 90-day outcome.

Researchers presenting preliminary late-breaking science presented on the first day of the American Stroke Association’s International Stroke Conference 2024 reported findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial. The results showed that giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later.

Giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later, according to preliminary late-breaking science presented today at the American Stroke Association's International Stroke Conference 2024.

Argatroban and eptifibatide were ineffective as adjunctive therapies to thrombolysis in patients with ischemic stroke in the MOST trial.

Phase III trial is the 'disappointing end of a long journey'

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

The International Stroke Conference 2024 will be held Feb. 7-9 in Phoenix, Arizona. According to program planners with the American Stroke Association, a division of the American Heart Association, findings from late-breaking science will include multiple high profile randomized clinical trials like RESILIENT-Extend, EMBOLISE, STEM, ZODIAC, among many others.

This randomized clinical trial examines the efficacy of argatroban plus altepase for acute ischemic stroke within 4.5 hours from onset.